Hepatitis C in people with mental illness: How big is the problem and how do we respond?

Australasian Psychiatry

Volumn 14, Issue 4, 2006, Pages 374-378

  Seccull, Alison ^a,e   Richmond, Jacqui ^b   Thomas, Ben ^c   Herrman, Helen ^d  

^a Victorian Public Health Training Scheme   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c St Vincent's Mental Health Service   (Australia)

^d Australia International Health Institute   (Australia)

^e NONE   (Australia)

Author keywords

Antiviral treatment; Hepatitis C; Mental illness; Screening

Indexed keywords

ANTIVIRUS AGENT; KAVA EXTRACT; PEGINTERFERON; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR;

ALCOHOL CONSUMPTION; ARTICLE; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; GOOD CLINICAL PRACTICE; HEPATITIS B; HEPATITIS C; HERBAL MEDICINE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MENTAL HEALTH SERVICE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT REFERRAL; PRACTICE GUIDELINE; PREVALENCE; PSYCHOSIS; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; VIRUS LOAD; WEIGHT REDUCTION;

AUSTRALIA; COMORBIDITY; COUNSELING; GUIDELINES; HEALTH EDUCATION; HEPATITIS C, CHRONIC; HUMANS; LIFE STYLE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; PREVALENCE; REFERRAL AND CONSULTATION;

EID: 33751078028     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1111/j.1440-1665.2006.02307.x     Document Type: Article

References (32)

1. Rosenberg SD, Goodman LA, Osher FC et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. American Journal of Public Health 2001; 91: 31.
2. Ellen S, Devlin H, Aizenstros J et al. HIV, Hepatitis B and C virus screening among psychiatry inpatients. Abstracts from the RANZCP 38th Congress Mutual Interests, 12-15 May 2003, Hobart, Tasmania. Australian and New Zealand Journal of Psychiatry 2003; 37 (Suppl. 1): A21.
3. Dore G, Grulich A, Hoy J et al. HIV/Viral Hepatitis A Guide for Primary Care, revised edn. Sydney: Australasian Society for HIV Medicine, 2004.
4. Chou R, Clark E, Helfand M. Screening for hepatitis C virus infection: A review of the evidence for the U.S. preventive services task force. Annals of International Medicine 2004; 140: 465-479.
5. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: Risks, screening, diagnosis, treatment, and interferon-based therapy complications. Journal of Psychiatric Practice 2003; 9: 93-110.
6. Meyer J. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: Results from oregon state hospital. Journal of Clinical Psychiatry 2003; 64: 540-545.
7. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299-1301.
8. Turpeinen P, Leinikki P, Seppala T et al. Drug abuse and viral hepatitis among psychiatric admissions to a Finnish psychiatric emergency ward. Nordic Journal of Psychiatry 1999; 53: 141-145.
9. Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ. Psychiatric comorbidity among hepatitis C-Positive patients. Psychosomatics 2001; 42: 411-415.
10. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS: Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report 2003. Sydney, NSW: The University of New South Wales, 2003.
11. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Risk factors for HIV/AIDS and hepatitis C among the chronic mentally ill. Australian and New Zealand Journal of Psychiatry 2001; 35: 203-209.
12. Australian National Council on AIDS.,Hepatitis C and Related Diseases. A Model of Care for the Management of Hepatitis C Infection in Adults. Sydney, NSW: Australian National Council on AIDS, Hepatitis C and Related Diseases, 2003.
13. Wilson JM, Jungner G. Principles and Practice of Screening for Disease (Public Health Paper Number 34). Geneva: World Health Organization, 1968.
14. Seymour C. Controversies in Management: Screening asymptomatic people at high risk for hepatitis C. British Medical Journal 1996; 312: 1347-1348.
15. Edlin BR, Seal KH, Lorvick J et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? New England Journal of Medicine 2001; 345: 211-215.
16. Ompad DC, Fuller CM, Vlahov D, Thomas D, Strathdee SA. Lack of Behavior Change among IDUs after HCV Infection. Clinical Infectious Disease 2002; 35: 783-788.
17. Brunette MF, Drake RE, Marsh BJ, Torrey WC, Rosenberg SD, Five-Site Health and Risk Study Research Committee. Responding to blood-borne infections among persons with severe mental illness. Psychiatric Services 2003; 54: 860-865.
18. Allison M, Mills PR. Controversies in management: Screening asymptomatic people at high risk for hepatitis C: The case against. British Medical Journal 1996; 312: 1349-1350.
19. Australian Hepatitis Council. Policy Series 2: Mental Health, July 2003. Australian Hepatitis Council: http://www.hepatitisaustralia.com/PDFs/ PolicySeries2.pdf. Accessed 7 October 2004.
20. Dore G. Sexual transmission of hepatitis C- is it a concern? Hepatitis C Review 2003; 41: 12.
21. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well? Annals of International Medicine 2004; 140: 370-381.
22. Therapeutic Goods Administration. Kava Fact Sheet, February 2004. Australian Hepatitis Council: http://www.tga.gov.au/cm/kavafs0402.htm. Accessed 7 October 2004.
23. Kidd M, Cheng W, Wilson S. Post-test counselling and initial management. Australian Family Physician (Special feature) 2003; 32: 26-29.
24. Rosenberg S, Brunette M, Oxman T, Marsh B et al. The STIRR model of best practices for blood-borne disease among clients with serious mental illness. Psychiatric Services 2004; 55: 660-664.
25. Harley H, Shaw D, Steven I. Ongoing management of hepatitis C. Australian Family Physician (Special feature) 2003; 32: 30-35.
26. Sylvestre DL. Injection drug use and Hepatitis C: From transmission to treatment. Psychiatric Annals 2003; 33: 377.
27. Loftis JM, Hauser P. Comanagement of depression and HCV treatment. Psychiatric Annals. 2003; 33: 385.
28. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-α-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104-112.
29. Cheung R, Ahmed A. Treating chronic hepatitis C patients with psychiatric disorders: An uphill battle. American Journal of Gastroenterology 2001; 96: 3-4.
30. Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-451.
31. Taylor LE, Schwartzapfel B, Allen S, Jacobs G, Mitty J. Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence. Clinical Infectious Diseases 2003; 36: 1501-1502.
32. Van Thiel DH, Friedlander L, De Maria N, Molloy P, Kania RJ, Colantoni A. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepato-Gastroenterology 1998; 45: 328-330.